ASH 2023 | Prognostic signature for FLT3-like wild type AML
Adrian Mosquera Orgueira, MD, PhD, University Hospital of Santiago de Compostela, A Coruña, Spain, discusses a signature capable of detecting patients with wild-type, FLT3-like disease in acute myeloid leukemia (AML). Patients with FLT3-like expression have wild-type FLT3, but their gene expression resembles that of patients with FLT3-mutant AML, and they respond to treatment with FLT3 inhibitor quizartinib as per the QUIWI trial (NCT04107727). The signature is capable of predicting responses to FLT3 inhibitors in wild-type FLT3-like AML patients, with certain mutations associated more strongly with greater quizartinib response. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
